These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
820 related articles for article (PubMed ID: 33361645)
1. Comparison of the immunogenicity & protective efficacy of various SARS-CoV-2 vaccine candidates in non-human primates. Mukhopadhyay L; Yadav PD; Gupta N; Mohandas S; Patil DY; Shete-Aich A; Panda S; Bhargava B Indian J Med Res; 2021 Jan & Feb; 153(1 & 2):93-114. PubMed ID: 33361645 [TBL] [Abstract][Full Text] [Related]
3. Immunogenicity and Reactogenicity of Vaccine Boosters after Ad26.COV2.S Priming. Sablerolles RSG; Rietdijk WJR; Goorhuis A; Postma DF; Visser LG; Geers D; Schmitz KS; Garcia Garrido HM; Koopmans MPG; Dalm VASH; Kootstra NA; Huckriede ALW; Lafeber M; van Baarle D; GeurtsvanKessel CH; de Vries RD; van der Kuy PHM; N Engl J Med; 2022 Mar; 386(10):951-963. PubMed ID: 35045226 [TBL] [Abstract][Full Text] [Related]
4. Immunogenicity and safety of NVX-CoV2373 as a booster: A phase 3 randomized clinical trial in adults. Raiser F; Davis M; Adelglass J; Cai MR; Chau G; Cloney-Clark S; Eickhoff M; Kalkeri R; McKnight I; Plested J; Zhu M; Dunkle LM; Vaccine; 2023 Sep; 41(41):5965-5973. PubMed ID: 37652823 [TBL] [Abstract][Full Text] [Related]
5. A human cell-based SARS-CoV-2 vaccine elicits potent neutralizing antibody responses and protects mice from SARS-CoV-2 challenge. He X; Ding L; Cao K; Peng H; Gu C; Li Y; Li D; Dong L; Hong X; Wang X; Fu M; Qiu C; Zhu C; Zhang Z; Song S; Wang C; Jiang Z; Xie Y; Qi Z; Zhao C; Zhao P; Zhang X; Xu J Emerg Microbes Infect; 2021 Dec; 10(1):1555-1573. PubMed ID: 34304724 [TBL] [Abstract][Full Text] [Related]
8. Immunogenicity and reactogenicity of SARS-CoV-2 vaccines in people living with HIV in the Netherlands: A nationwide prospective cohort study. Hensley KS; Jongkees MJ; Geers D; GeurtsvanKessel CH; Mueller YM; Dalm VASH; Papageorgiou G; Steggink H; Gorska A; Bogers S; den Hollander JG; Bierman WFW; Gelinck LBS; Schippers EF; Ammerlaan HSM; van der Valk M; van Vonderen MGA; Delsing CE; Gisolf EH; Bruns AHW; Lauw FN; Berrevoets MAH; Sigaloff KCE; Soetekouw R; Branger J; de Mast Q; Lammers AJJ; Lowe SH; de Vries RD; Katsikis PD; Rijnders BJA; Brinkman K; Roukens AHE; Rokx C PLoS Med; 2022 Oct; 19(10):e1003979. PubMed ID: 36301821 [TBL] [Abstract][Full Text] [Related]
9. Immunogenicity and protective efficacy of a recombinant protein subunit vaccine and an inactivated vaccine against SARS-CoV-2 variants in non-human primates. He Q; Mao Q; Peng X; He Z; Lu S; Zhang J; Gao F; Bian L; An C; Yu W; Yang F; Zhou Y; Yang Y; Li Y; Yuan Y; Yan X; Yang J; Wu X; Huang W; Li C; Wang J; Liang Z; Xu M Signal Transduct Target Ther; 2022 Mar; 7(1):69. PubMed ID: 35241645 [TBL] [Abstract][Full Text] [Related]
10. NVX-CoV2373-induced cellular and humoral immunity towards parental SARS-CoV-2 and VOCs compared to BNT162b2 and mRNA-1273-regimens. Hielscher F; Schmidt T; Klemis V; Wilhelm A; Marx S; Abu-Omar A; Ziegler L; Guckelmus C; Urschel R; Sester U; Widera M; Sester M J Clin Virol; 2022 Dec; 157():105321. PubMed ID: 36279695 [TBL] [Abstract][Full Text] [Related]
11. Comparison of antibody response durability of mRNA-1273, BNT162b2, and Ad26.COV2.S SARS-CoV-2 vaccines in healthcare workers. Brunner WM; Freilich D; Victory J; Krupa N; Scribani MB; Jenkins P; Lasher EG; Fink A; Shah A; Cross P; Bush V; Peek LJ; Pestano GA; Gadomski AM Int J Infect Dis; 2022 Oct; 123():183-191. PubMed ID: 36044963 [TBL] [Abstract][Full Text] [Related]
12. Neutralizing antibodies to SARS-CoV-2 variants of concern including Delta and Omicron in subjects receiving mRNA-1273, BNT162b2, and Ad26.COV2.S vaccines. Zhang GF; Meng W; Chen L; Ding L; Feng J; Perez J; Ali A; Sun S; Liu Z; Huang Y; Guo H; Gao SJ J Med Virol; 2022 Dec; 94(12):5678-5690. PubMed ID: 35902378 [TBL] [Abstract][Full Text] [Related]
14. NVX-CoV2373-induced T- and B-cellular immunity in immunosuppressed people with multiple sclerosis that failed to respond to mRNA and viral vector SARS-CoV-2 vaccines. Mueller-Enz M; Woopen C; Katoul Al Rahbani G; Haase R; Dunsche M; Ziemssen T; Akgün K Front Immunol; 2023; 14():1081933. PubMed ID: 37545513 [TBL] [Abstract][Full Text] [Related]
15. Immunogenicity Following Administration of BNT162b2 and Ad26.COV2.S COVID-19 Vaccines in the Pregnant Population during the Third Trimester. Citu IM; Citu C; Gorun F; Sas I; Tomescu L; Neamtu R; Motoc A; Gorun OM; Burlea B; Bratosin F; Malita D Viruses; 2022 Feb; 14(2):. PubMed ID: 35215900 [TBL] [Abstract][Full Text] [Related]